key: cord-0798264-pxehjh06
authors: Tré-Hardy, Marie; Cupaiolo, Roberto; Wilmet, Alain; Beukinga, Ingrid; Blairon, Laurent
title: Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers
date: 2021-06-20
journal: J Infect
DOI: 10.1016/j.jinf.2021.06.017
sha: d527d2c86a3372d3b5af56c99e6819c30ed728b9
doc_id: 798264
cord_uid: pxehjh06

nan

We read with interest the study recently published by Capetti and colleagues showing one-year 4 durability of anti-spike IgG after natural exposure to severe acute respiratory syndrome coronavirus 2 5 (SARS-CoV-2) 1 . Although the antibody kinetics in symptomatic and asymptomatic patients is known 1,2 , 6 we still ignore how it evolve beyond 6 months in vaccinees and if and how the initial serological status 7 of vaccinees might influence it. 8

To date, antibody kinetics data after vaccination remain fragmented. The study by 9 showed persistence of antibodies 6 months after the second dose of mRNA-1273 vaccine in 33 10 participants included in the phase 1 follow-up of the Moderna study without knowing their initial 11 serological status before the vaccination 3 . Likewise, interim results from a phase 3 trial of the mRNA-12 The quantitative analysis of the anti-SARS-CoV-2 IgG antibodies directed against the subunits (S1) and 23 (S2) of the virus spike protein was carried out using the LIAISON ® SARS-CoV-2 IgG kit (DiaSorin ® , 24 Saluggia, Italy) previously validated in our laboratory 8 and also used by Capetti et al 1 . Effectiveness of 25 the mRNA-1273 vaccine was also assessed through a medical questionnaire. Participants were asked 26 to declare any results of RT-qPCR tests regardless of the reason behind, even in asymptomatic 27 situations, and any eventual Covid-19 infection after vaccination (including severity of symptoms). To 28 better apprehend the observed efficacy, a comparison of the level of antibodies directed against the 29 nucleocapsid was carried out on part of the cohort of seronegative participants at T0 and T3 with the 30 Platelia® SARS-CoV-2 Total Ab test (Bio-Rad®) detecting total antibodies (IgM, IgA and IgG) (n=86/161). 31

Since only these antibodies are produced during a natural infection, their detection allows us to 1 identify the participants who have been infected by SARS-CoV-2 since their vaccination. 2

In the initially seronegative participants (n=161), we observed a persistence of anti-S-antibody levels 3 3 months after vaccination with nevertheless a decrease in the antibody levels observed between T2 4 and T3 in 48 participants ( Figure 1A) . Conversely, an increase in antibody levels was observed in 15 5 seronegative HCWs. Interestingly, in seropositive people (n=44), no drop in antibody was observed 6 between T2 and T3. The measured levels are all above the maximum quantification value (> 400 7 AU/mL). Moreover, the administration of a second dose of vaccine in participants initially seropositive 8 made it possible to catch-up the very few vaccinees (n=5) with a weaker response at T1 by reaching 9 the maximum level of antibodies at T2 ( Figure 1B) . 10

Analysis of the clinical follow-up questionnaires revealed that none of the respondents reported 11 thinking they had been infected (n=167). Thirty-six of them had to undergo a RT-qPCR and all were 12 negative. Finally, among the seronegative ones, only 2 participants developed antibodies directed 13 against the nucleocapsid at T3 while all were negative at T0 (n=86). Based on these results and given 14 that none of the participants developed symptoms, the mRNA-1273 vaccine is effective at preventing 15

Covid-19 illness. However, additional long-term serosurveillance studies based on larger cohorts will 16 be necessary to confirm these observations. Monitoring of anti-nucleocapsid antibodies remains a 17 complementary aid in detecting infections which are sometimes asymptomatic in vaccinated persons 18 known to be initially seronegative. 19

Faced with an unprecedented global vaccine deployment, a close follow-up of vaccinees remains 20 crucial to confirm both safety and long-lasting immune protection. In this study, we evaluated the 21 immune response of the participants but also the effectiveness of the mRNA-1273 vaccine in a context 22 different from the previous phase 1 and 3 studies by Moderna, under a higher virological pressure, 23 and by categorizing the participants into 2 cohorts according to their serological status at initiation. 24

Three months after vaccination, we confirm a very high efficacy and a persistence of anti-spike 25 antibodies. However, the decrease observed in some seronegative participants argues for an 26 additional dose of vaccine for this specific subgroup. the virus spike protein before (T0), 2 weeks after the first injection (T1), 2 weeks after the second 8 injection (T2) and 3 months after the first infection (T3) according to the participant serological status 9

(n = 205). The Box-and-Whisker plot represents the 25th and 75th percentiles. Inside the box, the 10 horizontal line indicates the median (the 50th percentile). Discs in light grey represent far out values. A 11

Wilcoxon test was used to assess the changes in IgG levels between T0, T1, T2 and T3 times within 12 seronegative (n=161) and seropositive subjects (n=44). A P-value < .05 was considered significant. 13 14 P < 0.0001 (overall) P < 0.0001 : T0 vs T1, T2, T3 P = 0.0625 : T1 vs T2/T3

351 spike variants bind human ACE2 with increased affinity

Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody

Acknowledgements: The authors thank all the members of the clinical laboratory staff for technical 1 assistance. We also thank the HCWs who participated in this study.